Sugi Predict

Sugi Predict / Targets / KCNK18

KCNK18

Potassium channel subfamily K member 18 · Q7Z418 · KCNK18 on Sugi Atlas →

256 patent compounds predicted against KCNK18, 128 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL29389546 SCHEMBL29389546 1.00 2/20
SCHEMBL20552766 SCHEMBL20552766 0.67 2/20
SCHEMBL20551827 SCHEMBL20551827 0.67 2/20
SCHEMBL25788464 SCHEMBL25788464 0.65 2/20
SCHEMBL21749236 SCHEMBL21749236 0.60 2/20
SCHEMBL25787885 SCHEMBL25787885 0.58 2/20
SCHEMBL20552499 SCHEMBL20552499 0.58 2/20
SCHEMBL20552917 SCHEMBL20552917 0.57 2/20
SCHEMBL20552361 SCHEMBL20552361 0.57 2/20
SCHEMBL20553148 SCHEMBL20553148 0.57 2/20
SCHEMBL21765141 SCHEMBL21765141 0.55 2/20
SCHEMBL21749268 SCHEMBL21749268 0.54 2/20
SCHEMBL20551742 SCHEMBL20551742 0.54 2/20
SCHEMBL21764737 SCHEMBL21764737 0.51 2/20
SCHEMBL25533411 SCHEMBL25533411 0.51 2/20
SCHEMBL21749299 SCHEMBL21749299 0.78 1/20
SCHEMBL339107 SCHEMBL339107 0.62 1/20
SCHEMBL24504902 SCHEMBL24504902 0.60 1/20
SCHEMBL31019421 SCHEMBL31019421 0.60 1/20
SCHEMBL22718160 SCHEMBL22718160 0.58 1/20

Clinical trials — most relevant to KCNK18 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR) PHASE4UNKNOWN
Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes PHASE4COMPLETED
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery PHASE4RECRUITING
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study PHASE4COMPLETED
Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2) PHASE2/PHASE3RECRUITING
Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels PHASE3COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy PHASE1/PHASE2RECRUITING
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK PHASE1COMPLETED
Phase I Study of SPH1188-11 in NSCLC PHASE1WITHDRAWN
Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC PHASE1UNKNOWN
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet PHASE1NOT_YET_RECRUITING
Mass Balance Study of [14C]HSK31858 in Healthy Adult Male Chinese Subjects. PHASE1ACTIVE_NOT_RECRUITING
Study to Determine the Effect of Food on the Blood Levels of AST2818 Following Single Oral Doses in Healthy Male Volunteers PHASE1COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy nanUNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) nanUNKNOWN
Characteristics of Andersen-Tawil Syndrome nanCOMPLETED
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia nanUNKNOWN
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome nanRECRUITING
Building of a Diagnostic/Prognostic Database for Human ERG Variant Effects nanRECRUITING
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients nanUNKNOWN
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats nanCOMPLETED
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KCNK18 binder may also engage these)

ProteinNameSimilarity
Q6VV64 — 0.996 Q6VV64 →
Q6Q1P3 — 0.991 Q6Q1P3 →
KCNK13 Potassium channel subfamily K member 13 0.976 landscape →
G3V8V5 — 0.972 G3V8V5 →
O88454 — 0.969 O88454 →
KCNK4 Potassium channel subfamily K member 4 0.967 landscape →
Q8R1P5 — 0.963 Q8R1P5 →
P97260 — 0.960 P97260 →
Q5MNU5 — 0.960 Q5MNU5 →
Q9ERS0 — 0.959 Q9ERS0 →
A2RRU4 — 0.959 A2RRU4 →
Q12770 — 0.959 Q12770 →
A6QM06 — 0.959 A6QM06 →
Q6GQT6 — 0.955 Q6GQT6 →
Q8MIQ9 — 0.955 Q8MIQ9 →
Q9R283 — 0.953 Q9R283 →
Q3TD49 — 0.953 Q3TD49 →
Q04671 — 0.952 Q04671 →
KCNK17 Potassium channel subfamily K member 17 0.952 landscape →
SPPL2B Signal peptide peptidase-like 2B 0.951 landscape →
Q49LS8 — 0.951 Q49LS8 →
Q5T848 — 0.951 Q5T848 →
Q9HB15 — 0.950 Q9HB15 →
Q9ERS1 — 0.950 Q9ERS1 →
E1BBQ2 — 0.950 E1BBQ2 →
D4A6L0 — 0.950 D4A6L0 →
Q5F383 — 0.950 Q5F383 →
D4AD53 — 0.949 D4AD53 →
Q9WTN5 — 0.949 Q9WTN5 →
Q9UIX4 — 0.949 Q9UIX4 →